

Table S1 Definitions of baseline characteristics, comorbidities and treatment

Variable	Definitions
Baseline characteristics	
Smoking status	Per chart review, current or former smoker
Insurance status	Per chart review, medicaid, medicare, private or uninsured
Comorbidities	
Diabetes mellitus	Per chart review, insulin and non-insulin dependent
Hypertension	Per chart review
Coronary artery disease	Per chart review, any history of angina, myocardial infarction, stent placement or coronary artery bypass graft surgery
Congestive heart failure	Per chart review, heart failure with preserved versus reduced ejection fraction
Hyperlipidemia	Per chart review
Chronic kidney disease	Per chart review, baseline eGFR <60 (excludes any patients on current hemodialysis or peritoneal dialysis)
COPD	Per chart review
Asthma	Per chart review
Obstructive sleep apnea	Per chart review
End stage renal disease on dialysis	Per chart review, patients on hemodialysis or peritoneal dialysis
Chronic liver disease	Per chart review, cirrhosis, alcohol related liver disease, nonalcoholic fatty liver disease, autoimmune hepatitis, hepatitis B or C, primary biliary cirrhosis
Cancer	Per chart review (other than non-melanoma skin cancer), cancer of the breast, colorectal, prostate, gastric, pancreatic, melanoma, brain, ovarian, blood or other
Stroke	Per chart review; ischemic or hemorrhagic
HIV	Per chart review, any history of HIV or AIDS
Treatment	
Antibiotics	Oral or intravenous antibiotics for pneumonia during admission
Remdesivir	Per chart review, criteria—laboratory confirmed SARS-CoV-2, respiratory symptoms onset ≤ 10 days, $SpO_2 \leq 94\%$ on room air and requiring supplemental oxygen, radiographic evidence of pulmonary infiltrates on chest X-ray or CT scan
Anticoagulation	Therapeutic anticoagulation (continued home anticoagulation therapy if indicated or), criteria—new deep vein thrombosis, pulmonary embolism or D-dimer ≥ 3 mg/L at admission
Tocilizumab	Per chart review, criteria— ≤ 7 days from hospitalization, worsening of respiratory status and received ≥ 24 hours of corticosteroids, ≤ 24 hours from initiating respiratory (HFNC > 30 L/min and $FiO_2 > 0.4$, NIV or MV) or cardiovascular organ support and CRP ≥ 75 mg/L. Also, approval from infectious diseases needed
Corticosteroids	Per chart review, dexamethasone, methylprednisolone, prednisone or hydrocortisone. Criteria— $SpO_2 \leq 94\%$ on room air, new supplemental oxygen requirement or mechanical ventilation

eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SpO_2 , oxygen saturation; HFNC, high-flow nasal cannula oxygen therapy; FiO_2 , fraction of inspiration O_2 ; NIV, noninvasive ventilation; MV, mechanical ventilation; CRP, C-reaction protein.